Continuous infusion (CI) bleomycin in AIDS-related Kaposi's sarcoma (KS) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Continuous infusion (CI) bleomycin in AIDS-related Kaposi's sarcoma (KS) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A1118 1993. Unique Identifier : AIDSLINE ICDB/93692094
Reddy M; Remick S; Herman D; Willis K; Grace C; McSharry J; Horton J; Harper G; Albany Medical Coll., Albany, NY 12208

Abstract: Bleomycin is an active drug in KS, is cell-cycle phase-specific, and has a short terminal half-life, characteristics which make it suitable for CI. We administered 20 mg/m2/day as a 24-hr CI for 3 days to 17 patients (pts) with AIDS-related KS. All pts had biopsy-proven KS and measurable disease. Nine pts (53%) had bronchoscopically proven KS, and only 2 pts had received prior cytotoxic chemotherapy. A total of 53 cycles were administered. Toxicity was limited. There were 12 episodes of grade 3 and 1 episode of grade 4 neutropenia, no significant thrombocytopenia, and no episodes of febrile neutropenia. There were 5 infectious complications including a life-threatening episode of Clostridium septicemia. Of the first 15 pts treated, 5 partial remissions (33%) were observed using ECOG criteria and 8 pts (53%) responded by ACTG criteria (JCO 7:1201, 1989). Bleomycin by CI is active in pts with advanced AIDS-related KS with modest myelosuppression.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Bleomycin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Administration Schedule Female Human Infusions, Intravenous Male Sarcoma, Kaposi's/*DRUG THERAPY Skin Neoplasms/*DRUG THERAPY ABSTRACTKWDacquiredimmunodeficiencysyndrome/KWDdrugtherapybleomycin/KWDadministration&dosage/adverseeffectsdrugadministrationschedulefemalehumaninfusions,intravenousmalesarcoma,kaposi's/KWDdrugtherapyskinneoplasms/KWDdrugtherapyabstract
930730
M9370994

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .